Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Nichi-Iko Recall Hits Towa’s Teprenone Supply
April 23, 2020
- Pfizer Japan Further Extends Work-from-Home through May-End
April 23, 2020
- Remicade Biosimilars OK’ed for Behcet’s-Associated Uveitis
April 23, 2020
- Ube Industries to Start Avigan Intermediate Supplies from July
April 23, 2020
- Myovant Files Relugolix for Advanced Prostate Cancer in US
April 23, 2020
- JCR to Develop 2 Mucopolysaccharidosis Drugs Using BBB-Penetrating Technology
April 23, 2020
- Japan Heading into Earnings Season amid Coronavirus Woes
April 22, 2020
- Shin Nippon Biomedical Joins AnGes Vaccine Development
April 22, 2020
- Drug Makers Restricting Nafamostat Supplies as Hopes Grow for Its Repurposing for COVID-19
April 22, 2020
- Ehime Univ., Sumitomo Dainippon Decipher Mechanism of Action of Malaria Vaccine Candidate
April 22, 2020
- Positive Data in Hand, Ono/Takeda to Seek 1st-Line RCC Nod for Opdivo/Cabometyx Combo
April 22, 2020
- Astellas Scoops Up UK's Mitochondria-Focused Biotech Nanna
April 22, 2020
- Sawai Curbing Shipments for 2 More Drugs after Nichi-Iko’s Massive Recalls
April 21, 2020
- Sumitomo Dainippon Chair Sees No Need for Further Consolidation among Japan Drug Makers
April 21, 2020
- Otsuka Grabs Japan Rights to Esperion’s Cholesterol Drug
April 21, 2020
- JCR Closes ArmaGen Buyout, Gaining IP Rights on Blood-Brain Barrier-Penetrating Technology
April 21, 2020
- Otsuka, Meiji Put Off Earnings Announcement amid COVID-19 Outbreak
April 21, 2020
- Japan Generic Makers’ New Grad Hiring Logs 1st Increase Since FY2016
April 20, 2020
- Some Drug Makers Rejuvenating Workforce by Boosting New Hires after Job Cuts: Jiho Survey
April 20, 2020
- Towa, Osaka Psychiatric Medical Center Pair Up on Novel Biomarker Research for AD
April 20, 2020
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…